SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
-10.11%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$301M
AUM Growth
+$301M
(+8.6%)
Cap. Flow
+$56M
Cap. Flow
% of AUM
18.61%
Top 10 Holdings %
Top 10 Hldgs %
83.86%
Holding
26
New
5
Increased
13
Reduced
3
Closed
3
Top Buys
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$25.5M |
| 2 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$12.3M |
| 3 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$6.66M |
| 4 |
Evolus
EOLS
|
$6.15M |
| 5 |
Galapagos
GLPG
|
$4.14M |
Top Sells
| 1 |
THRD
Third Harmonic Bio
THRD
|
$13.4M |
| 2 |
UroGen Pharma
URGN
|
$4.64M |
| 3 |
Castle Biosciences
CSTL
|
$1.26M |
| 4 |
MaxCyte
MXCT
|
$640K |
| 5 |
SCYNEXIS
SCYX
|
$214K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
UroGen Pharma
URGN
$900M
| – | – | -448,508 | Closed | -$4.64M |
|